Table 1 Patient and transplant characteristics
|  | 7.5 mg group (N = 203) | 10.0 mg group (N = 205) | P |
|---|---|---|---|
Patient age, median (range), years | 28 (14–59) | 26 (14–57) | 0.324 |
Gender, male/female, n (%) | 139 (68.5)/64 (31.5) | 139 (67.5)/66 (32.2) | 0.885 |
Primary diseases, n (%) | Â | Â | 0.483 |
 AML (cytogenetics) | 99 (48.8) | 95 (46.3) |  |
  Better risk | 8 (8.1) | 7 (7.4) |  |
  Intermediate risk | 41 (41.4) | 41 (43.1) |  |
  Poor risk | 36 (36.4) | 32 (33.7) |  |
  Unknown | 14 (14.1) | 15 (15.8) |  |
 ALL | 94 (46.3) | 94 (45.6) |  |
  Ph positive | 29 (30.9) | 31 (33.0) |  |
  Ph negative | 65 (69.1) | 63 (67.0) |  |
 ABL/ALAL | 10 (4.9) | 16 (7.8) |  |
Number of courses of chemotherapy before transplantation, median (range) | 3 (3–9) | 3 (3–7) | 0.875 |
Status of primary disease, n (%) | Â | Â | 0.318 |
 CR1 | 155 (76.4) | 143 (69.7) |  |
 ≥ CR2 | 10 (4.9) | 12 (5.9) |  |
 Non-CR | 38 (18.7) | 50 (24.4) |  |
Conditioning, n (%) | Â | Â | 0.164 |
 Standard myeloablative regimen | 165 (81.3) | 155 (75.6) |  |
 Intensified conditioning | 38 (18.7) | 50 (24.3) |  |
No. of HLA mismatched, n (%) | Â | Â | 0.479 |
 1 | 14 (6.9) | 15 (7.3) |  |
 2–3 | 51 (25.1) | 62 (30.2) |  |
 4–5 | 138 (68.0) | 128 (62.1) |  |
Donor age, median (range), years | 38 (10–59) | 40 (15–59) | 0.326 |
Donor–recipient sex match, n (%) |  |  | 0.850 |
 Male–male | 90 (44.3) | 92 (44.9) |  |
 Male–female | 41 (20.2) | 47 (22.9) |  |
 Female–male | 55 (27.1) | 52 (25.4) |  |
 Female–female | 17 (8.4) | 14 (6.8) |  |
CMV serostatus, n (%) | Â | Â | 0.906 |
 D−/R− | 8 (3.9) | 10 (4.9) |  |
 D+/R− | 7 (3.4) | 7 (3.4) |  |
 D−/R+ | 5 (2.5) | 7 (3.4) |  |
 D+/R+ | 183 (90.1) | 181 (88.3) |  |
EBV serostatus, n (%) | Â | Â | 0.940 |
 D−/R− | 9 (4.4) | 10 (4.9) |  |
 D+/R− | 47 (23.2) | 50 (24.3) |  |
 D−/R+ | 34 (16.7) | 30 (14.6) |  |
 D+/R+ | 113 (55.7) | 115 (56.1) |  |
Median CD34+ cells per graft, × 106/kg (range) | 2.26 (0.32–7.37) | 2.58 (0.71–7.39) | 0.205 |